Clinical trial · Observational
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)
Utilizing Intraprocedural Flow and Perfusion Dynamics as a Predictor of Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Chemoembolization and Radioembolization (Y90) "Liver Embolization Perfusion TACE Study (Version 1.0) EPTS 2013-1.0"
NCT02093104CI-TRIAL-00027419TACEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Undergoing Chemoembolization and Radioembolization | — | UNRESOLVED | — |
| Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Liver Tumour Perfusion using CT & C-arm systems in 40 patients at VGH over a 3 month period
- timeFrame
- 3 months
- description
- The purpose of this protocol is to study the potential predictive and prognostic value of tumor perfusion assessment utilizing computed tomography and C-arm systems in the treatment of liver tumors. Observational nature of study; post hoc analysis precludes determination of primary endpoint. 3 month follow-up CT scans as per protocol involving standard of care 4 phase CT scan in addition to perfusion CT Utilizing intraprocedural flow and perfusion dynamics as a predictor of response in 40 patients with unresectable hepatocellular carcinoma undergoing intraprocedural flow and perfusion dynamics as a predictor of response in chemoembolization and radioembolization (Y90)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histological or cytological diagnosis or meet the AASLD criteria for diagnosis of hepatocellular carcinoma (HCC) and at least one uni-dimensional lesion measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria by CT-scan 2. OR radiologic evidence of liver metastatic disease 3. Amenable to embolization or ablation as adjuvant, neoadjuvant or definitive (curative or palliative) therapy. 4. Adult \> 19 years old and estimated life expectancy over 3 months 5. Eastern Cooperative Oncology Group (ECOG) performance status under or equals 1 6. Adequate haematological function: Hb over or equals 9g/100mL, absolute neutrophil count over or equals 1 500/mm3, platelet count over or equals 50 000/mm3 7. Adequate renal function; serum creatinine under 150μmol/L 8. Bilirubin under or equals 50 µmol/L, Aspartate aminotransferase (AST) or ALT uner or equals 5 x upper limit of normal (ULN), international normalized ratio (INR) under or equals 1.5 9. Liver cirrhosis Child Pugh A - B7 10. Ability to provide written informed consent Exclusion Criteria: 1. Advanced liver disease with Child-Pugh score over 7 or active gastrointestinal bleeding or encephalopathy or ascites refractory to diuretic therapy 2. Women who are pregnant or breast feeding 3. Allergy to contrast media 4. Contraindication to hepatic artery catheterisation, such as severe peripheral vascular disease precluding catheterisation OR contraindication to locally curative ablation due to size, location or shape. 5. Psychiatric or other disorder likely to impact on informed consent 6. Patient unable and/or unwilling to comply with treatment and study instructions
References
Publications (0)
Data not yet available
No reference posted for this study.